Apellis
Edit

Apellis

http://apellis.com/
Last activity: 10.06.2024
Active
Categories: DevelopmentLearnMedtechScienceWebsite
Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Followers
1.23K
Website visits
46.5K /mo.
Mentions
40
Location: United States, Massachusetts, Waltham
Employees: 201-500
Total raised: $140.1M
Founded date: 2009

Investors 10

Funding Rounds 3

DateSeriesAmountInvestors
10.08.2017Series E$60M-
12.02.2016Series D$47.1M-
02.12.2014-$33M-

Mentions in press and media 40

DateTitleDescription
10.06.2024Sobi to present new data across its haematology portfolio at the 2024 EHA congressSobi to present new data across its haematology portfolio at the 2024 EHA congress Mon, Jun 10, 2024 12:15 CET Report this content Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid...
24.05.2024Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congressPositive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress Fri, May 24, 2024 16:05 CET Report this content Rapid reduction in disease activity seen at 12 weeks sustained at one year 55% of patients sho...
08.05.2024Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNHAspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH Wed, May 08, 2024 10:15 CET Report this content Sobi® today announced that the European Commission (EC) has approved an indication extension ...
07.05.2024Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C.Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024. Three-day event brings together patients, care partners, and public health champions to ad...
01.05.2024Prevent Blindness to Host 13th Annual Focus on Eye Health Summit, a Two-Day Virtual Interactive Event, with theme of "Being Seen and Heard"Registration open for free 13th Annual Prevent Blindness Focus on Eye Health Summit, held virtually, July 10 and 11, 2024. National nonprofit Prevent Blindness to hold the 2024 Focus on Eye Health Summit, a free virtual interactive event, J...
06.03.2024Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)-
30.11.2022Prevent Blindness Declares Second Annual Geographic Atrophy Awareness Week as Dec. 5-11, 2022Prevent Blindness declares Dec. 5-11, 2022, as the second annual Geographic Atrophy Awareness Week, providing free educational resources to the public. “New research and treatment options are promising for geographic atrophy,” said Jeff Tod...
26.01.2022Prevent Blindness Declares February as Age-related Macular Degeneration (AMD) and Low Vision Awareness MonthPrevent Blindness declares February as Age-related Macular Degeneration (AMD), and Low Vision Awareness Month. “The good news is that vision loss from AMD can be significantly slowed if the eye disease is diagnosed and treated early,” said ...
15.12.2021Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNHAspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH Wed, Dec 15, 2021 13:00 CET The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demon...
13.12.2021Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clinical measures in a broad PNH patient populationImprovements demonstrated in treatment-naïve patients and patients with baseline haemoglobin levels greater than or equal to 10.0 g/dL Data were presented at the American Society of Hematology (ASH) Annual Meeting Swedish Orphan Biovitrum A...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In